{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-359961","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2021-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.948493+00:00","generated_at":"2026-06-28T00:10:40.146722+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs","bullets":["CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.","Melian will serve in an advisory role for transition; CEO thanked him for advancing posoleucel into Phase 3.","Richard Riese, MD, PhD, SVP Clinical Research, will oversee clinical development including Phase 3 posoleucel studies.","Company's pipeline of virus-specific T cells continues; no change to clinical strategy disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-359961","json":"https://secwatch.observer/filing/0001193125-21-359961.json","markdown":"https://secwatch.observer/filing/0001193125-21-359961.md","text":"https://secwatch.observer/filing/0001193125-21-359961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/0001193125-21-359961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/d256659d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T00:10:40.146722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}